PMID- 27891093
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220310
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 7
DP  - 2016
TI  - Targeting Strategies for Renal Cell Carcinoma: From Renal Cancer Cells to Renal 
      Cancer Stem Cells.
PG  - 423
LID - 423
AB  - Renal cell carcinoma (RCC) is a common form of urologic tumor that originates 
      from the highly heterogeneous epithelium of renal tubules. Over the last decade, 
      targeting therapies to renal cancer cells have transformed clinical care for RCC. 
      Recently, it was proposed that renal cancer stem cells (CSCs) isolated from renal 
      carcinomas were responsible for driving tumor growth and resistance to 
      conventional chemotherapy and radiotherapy, according to the theory of CSCs; this 
      has provided the rationale for therapies targeting this aggressive cell 
      population. Precise identification of renal CSC populations and the complete cell 
      hierarchy will accurately inform characterization of disease subtypes. This will 
      ultimately contribute to more personalized and targeted therapies. Here, we 
      summarize potential targeting strategies for renal cancer cells and renal CSCs, 
      including tyrosine kinase inhibitors, mammalian target of rapamycin inhibitors 
      (mTOR), interleukins, CSC marker inhibitors, bone morphogenetic protein-2, 
      antibody drug conjugates, and nanomedicine. In conclusion, targeting therapies 
      for RCC represent new directions for exploration and clinical investigation and 
      they plant a seed of hope for advanced clinical care.
FAU - Yuan, Zhi-Xiang
AU  - Yuan ZX
AD  - Department of Pharmacy, College of Veterinary Medicine, Sichuan Agricultural 
      University Chengdu, China.
FAU - Mo, Jingxin
AU  - Mo J
AD  - Key Laboratory for Stem Cells and Tissue Engineering, Ministry of Education, Sun 
      Yat-sen UniversityGuangzhou, China; Department of Histology and Embryology, 
      Zhongshan School of Medicine, Sun Yat-sen UniversityGuangzhou, China.
FAU - Zhao, Guixian
AU  - Zhao G
AD  - Department of Pharmacy, College of Veterinary Medicine, Sichuan Agricultural 
      University Chengdu, China.
FAU - Shu, Gang
AU  - Shu G
AD  - Department of Pharmacy, College of Veterinary Medicine, Sichuan Agricultural 
      University Chengdu, China.
FAU - Fu, Hua-Lin
AU  - Fu HL
AD  - Department of Pharmacy, College of Veterinary Medicine, Sichuan Agricultural 
      University Chengdu, China.
FAU - Zhao, Wei
AU  - Zhao W
AD  - Key Laboratory for Stem Cells and Tissue Engineering, Ministry of Education, Sun 
      Yat-sen UniversityGuangzhou, China; Department of Histology and Embryology, 
      Zhongshan School of Medicine, Sun Yat-sen UniversityGuangzhou, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20161110
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC5103413
OTO - NOTNLM
OT  - renal cancer
OT  - renal cancer stem cells
OT  - renal cell carcinoma
OT  - surface markers
OT  - targeting strategies
EDAT- 2016/11/29 06:00
MHDA- 2016/11/29 06:01
PMCR- 2016/11/10
CRDT- 2016/11/29 06:00
PHST- 2016/08/10 00:00 [received]
PHST- 2016/10/25 00:00 [accepted]
PHST- 2016/11/29 06:00 [entrez]
PHST- 2016/11/29 06:00 [pubmed]
PHST- 2016/11/29 06:01 [medline]
PHST- 2016/11/10 00:00 [pmc-release]
AID - 10.3389/fphar.2016.00423 [doi]
PST - epublish
SO  - Front Pharmacol. 2016 Nov 10;7:423. doi: 10.3389/fphar.2016.00423. eCollection 
      2016.